ArticleJournal of contemporary brachytherapy2026
Computed tomography-based customized surface mould high-dose-rate brachytherapy for non-melanoma skin cancer of the scalp and face. Long-term results: Optimizing for reduction of late toxicity and improving cosmetic outcome.
Article in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Early-stage non-melanoma skin cancer (NMSC) is usually treated with surgical excision with or without adjuvant radiotherapy. Tumor location on facial sub-sites may lead to poor cosmetic outcomes with surgery. Surface mould brachytherapy offers better conformality, reduced treatment duration, and comparable local control and cosmetic outcomes. Material and methods: Twenty-eight patients with NMSC of the face or scalp received definitive or adjuvant radiotherapy using a customized surface mould brachytherapy technique. Prescription dose was 3,500-4,200 cGy in 9-12 fractions. Clinical target volume (CTV) V Results: Thirteen (46.4%), six (21.4%), and eight (28.6%) patients experienced grade 2 acute skin, late skin, and late subcutaneous toxicity, respectively. Among grade 3 toxicity, only 1 acute skin toxicity was observed. All patients had either excellent or good cosmetic outcomes, while 0.1 cc, 1 cc, 2 cc skin dose, and homogeneity index were significant predictors of late skin, subcutaneous toxicity, and cosmetic outcome. For cosmesis, the distance from catheter midpoint to skin surface was also a significant predictor of outcome. After a median follow-up of 54 months, no disease recurrence was observed in the study cohort. Conclusions: Surface mould brachytherapy can provide excellent local control and cosmetic outcome for the treatment of NMSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.